Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease

Journal of Neuroscience

Volumn 29, Issue 30, 2009, Pages 9651-9659

  Voutilainen, Merja H ^a   Bäck, Susanne ^a   Pörsti, Eeva ^a   Toppinen, Liisa ^a   Lindgren, Lauri ^a   Lindholm, Päivi ^b   Peränen, Johan ^b   Saarma, Mart ^b   Tuominen, Raimo K ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IODINE 125; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AUTORADIOGRAPHY; BEHAVIORAL RESEARCH; CELL CONTACT; CELL FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TRANSPORT; FRONTAL CORTEX; GAMMA RADIATION; IMMUNOHISTOCHEMISTRY; INJECTION SITE; ISOTOPE LABELING; MALE; MESENCEPHALON; NERVE CELL DEGENERATION; NERVE CELL GROWTH; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; RADIATION DETECTION; RAT; SINGLE DRUG DOSE; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 68049127516     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0833-09.2009     Document Type: Article

References (56)

1. Anderson KD, Alderson RF, Altar CA, DiStefano PS, Corcoran TL, Lindsay RM, Wiegand SJ (1995) Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low-affinity neurotrophin receptors. J Comp Neurol 357:296-317.
2. Apostolou A, Shen Y, Liang Y, Luo J, Fang S (2008) Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res 314:2454-2467.
3. Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68-74.
4. Björklund A, Rosenblad C, Winkler C, Kirik D (1997) Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200. (Pubitemid 27465509)
5. Cadet JL, Zhu SM (1992) The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res 595:316-326.
6. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18:1162-1164. (Pubitemid 39561557)
7. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909.
8. Di Stefano A, Sozio P, Cerasa LS (2008) Antiparkinson prodrugs. Molecules 13:46-68.
9. DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, Schick CM, Lindsay RM, Wiegand SJ (1992) The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 8:983-993.
10. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255. (Pubitemid 26090648)
11. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595. (Pubitemid 36597106)
12. Ginty DD, Segal RA (2002) Retrograde neurotrophin signaling: Trk-ing along the axon. Curr Opin Neurobiol 12:268-274.
13. Hamilton JF, Morrison PF, Chen MY, Harvey-White J, Pernaute RS, Phillips H, Oldfield E, Bankiewicz KS (2001) Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 168:155-161. (Pubitemid 32195267)
14. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111. (Pubitemid 24362034)
15. Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E Jr, Milbrandt J, Rosenthal A, Björklund A, Vandlen RA, Hynes MA, Phillips HS (1998) Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18:4929-4937. (Pubitemid 28285401)
16. Hou JG, Lin LF, Mytilineou C (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 66:74-82.
17. Kearns CM, Gash DM (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111.
18. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM (1997) GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17:7111-7118. (Pubitemid 27427888)
19. Kirik D, Rosenblad C, Björklund A (2000) Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12:3871-3882. (Pubitemid 30836273)
20. Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, Milbrandt J (1996) Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467-470.
21. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466. (Pubitemid 43358066)
22. Lapchak PA, Jiao S, Collins F, Miller PJ (1997) Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 747:92-102. (Pubitemid 27063803)
23. Laurikainen A, Hiltunen JO, Vanhatalo S, Klinge E, Saarma M (2000) Glial cell line-derived neurotrophic factor is expressed in penis of adult rat and retrogradely transported in penile parasympathetic and sensory nerves. Cell Tissue Res 302:321-329.
24. Lee CS, Sauer H, Björklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72:641-653. (Pubitemid 26124689)
25. Leitner ML, Molliver DC, Osborne PA, Vejsada R, Golden JP, Lampe PA, Kato AC, Milbrandt J, Johnson EM Jr (1999) Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci 19:9322-9331.
26. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448:73-77. (Pubitemid 47037006)
27. Lindholm P, Peränen J, Andressoo JO, Kalkkinen N, Kokaia Z, Lindvall O, Timmusk T, Saarma M (2008) MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 39:356-371.
28. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7:400-408.
29. Mizobuchi N, Hoseki J, Kubota H, Toyokuni S, Nozaki J, Naitoh M, Koizumi A, Nagata K (2007) ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell Struct Funct 32:41-50. (Pubitemid 350086449)
30. Mufson EJ, Kroin JS, Sobreviela T, Burke MA, Kordower JH, Penn RD, Miller JA (1994) Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat. Exp Neurol 129:15-26. (Pubitemid 24344153)
31. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57:451-484.
32. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 19:267-271.
33. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF; ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor (2003) Randomized, double-blind trial of glial cell linederived neurotrophic factor (GDNF) in PD. Neurology 60:69-73. (Pubitemid 36070646)
34. Oiwa Y, Yoshimura R, Nakai K, Itakura T (2002) Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947:271-283. (Pubitemid 34899514)
35. Palgi M, Lindström R, Peränen J, Piepponen TP, Saarma M, Heino TI (2009) Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc Natl Acad Sci U S A 106:2429-2434.
36. Parkash V, Lindholm P, Peränen J, Kalkkinen N, Oksanen E, Saarma M, Leppanen VM, Goldman A (2009) The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng Des Sel 22:233-241.
37. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. San Diego: Academic.
38. Peränen J, Rikkonen M, Hyvönen M, Kääriäinen L (1996) T7 vectors with modified T7lac promoter for expression of proteins in Escherichia coli. Anal Biochem 236:371-373.
39. Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20:173-188. (Pubitemid 36693821)
40. Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW (2004) Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res 146:168-183. (Pubitemid 37541383)
41. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647.
42. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A (1999) Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11:1554-1566. (Pubitemid 29192230)
43. Sachs C, Jonsson G, Heikkila R, Cohen G (1975) Control of the neurotoxicity of 6-hydroxydopamine by intraneuronal noradrenaline in rat iris. Acta Physiol Scand 93:345-351.
44. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA, GashDM (2006) Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202:497-505. (Pubitemid 44692690)
45. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415. (Pubitemid 24098798)
46. Shults CW, Kimber T, Martin D (1996) Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 7:627-631. (Pubitemid 26106185)
47. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell linederived neurotrophic factor. J Neurosurg 102:216-222. (Pubitemid 43194069)
48. Sonsalla PK, Albers DS, Zeevalk GD (1998) Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14:69-74.
49. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995a) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
50. Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ, Olson L (1995b) Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci U S A 92:8274-8278.
51. Turski L, Bressler K, Rettig KJ, Löschmann PA, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D- aspartate antagonists. Nature 349:414-418.
52. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.
53. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
54. Winkler C, Sauer H, Lee CS, Björklund A (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16:7206-7215. (Pubitemid 26382897)
55. Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM (1997) Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282:1396-1401. (Pubitemid 27408321)
56. Zhou C, Xiao C, Commissiong JW, Krnjević K, Ye JH (2006) Mesencephalic astrocyte-derived neurotrophic factor enhances nigral gammaaminobutyric acid release. Neuroreport 17:293-297. (Pubitemid 43298021)